Literature DB >> 22544318

Epigenetic inactivation of the tumor suppressor BIN1 drives proliferation of SNF5-deficient tumors.

Elizabeth S McKenna1, Pablo Tamayo, Yoon-Jae Cho, Erik J Tillman, E Lorena Mora-Blanco, Courtney G Sansam, Edward C Koellhoffer, Scott L Pomeroy, Charles W M Roberts.   

Abstract

Emerging evidence demonstrates that subunits of the SWI/SNF chromatin remodeling complex are specifically mutated at high frequency in a variety of human cancer types. SNF5 (SMARCB1/INI1/BAF47), a core subunit of the SWI/SNF complex, is inactivated in the vast majority of rhabdoid tumors (RT), an aggressive type of pediatric cancer. SNF5-deficient cancers are diploid and genomically stable, suggesting that epigenetically based changes in transcription are key drivers of tumor formation caused by SNF5 loss. However, there is limited understanding of the target genes that drive cancer formation following SNF5 loss. Here we performed comparative expression analyses upon three independent SNF5-deficient cancer data sets from both human and mouse and identify downregulation of the BIN1 tumor suppressor as a conserved event in primary SNF5-deficient cancers. We show that SNF5 recruits the SWI/SNF complex to the BIN1 promoter, and that the marked reduction of BIN1 expression in RT correlates with decreased SWI/SNF occupancy. Functionally, we demonstrate that re-expression of BIN1 specifically compromises the proliferation of SNF5-deficient RT cell lines. Identification of BIN1 as a SNF5 target gene reveals a novel tumor suppressive regulatory mechanism whose disruption can drive cancer formation.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22544318      PMCID: PMC3359122          DOI: 10.4161/cc.20280

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  58 in total

Review 1.  Endocytic proteins in the regulation of nuclear signaling, transcription and tumorigenesis.

Authors:  Beata Pyrzynska; Iwona Pilecka; Marta Miaczynska
Journal:  Mol Oncol       Date:  2009-06-11       Impact factor: 6.603

2.  Bin1 mediates apoptosis by c-Myc in transformed primary cells.

Authors:  J B DuHadaway; D Sakamuro; D L Ewert; G C Prendergast
Journal:  Cancer Res       Date:  2001-04-01       Impact factor: 12.701

Review 3.  SWI/SNF nucleosome remodellers and cancer.

Authors:  Boris G Wilson; Charles W M Roberts
Journal:  Nat Rev Cancer       Date:  2011-06-09       Impact factor: 60.716

4.  Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma.

Authors:  Siân Jones; Tian-Li Wang; Ie-Ming Shih; Tsui-Lien Mao; Kentaro Nakayama; Richard Roden; Ruth Glas; Dennis Slamon; Luis A Diaz; Bert Vogelstein; Kenneth W Kinzler; Victor E Velculescu; Nickolas Papadopoulos
Journal:  Science       Date:  2010-09-08       Impact factor: 47.728

5.  Aurora A is a repressed effector target of the chromatin remodeling protein INI1/hSNF5 required for rhabdoid tumor cell survival.

Authors:  Seungjae Lee; Velasco Cimica; Nandini Ramachandra; David Zagzag; Ganjam V Kalpana
Journal:  Cancer Res       Date:  2011-04-26       Impact factor: 12.701

6.  Frequent BRG1/SMARCA4-inactivating mutations in human lung cancer cell lines.

Authors:  Pedro P Medina; Octavio A Romero; Takashi Kohno; Luis M Montuenga; Ruben Pio; Jun Yokota; Montse Sanchez-Cespedes
Journal:  Hum Mutat       Date:  2008-05       Impact factor: 4.878

7.  RhoA-dependent regulation of cell migration by the tumor suppressor hSNF5/INI1.

Authors:  Julie Caramel; Frédérique Quignon; Olivier Delattre
Journal:  Cancer Res       Date:  2008-08-01       Impact factor: 12.701

Review 8.  Epigenetics and cancer without genomic instability.

Authors:  Elizabeth S McKenna; Charles W M Roberts
Journal:  Cell Cycle       Date:  2009-01-30       Impact factor: 4.534

9.  Loss of BRG1/BRM in human lung cancer cell lines and primary lung cancers: correlation with poor prognosis.

Authors:  David N Reisman; Janiece Sciarrotta; Weidong Wang; William K Funkhouser; Bernard E Weissman
Journal:  Cancer Res       Date:  2003-02-01       Impact factor: 12.701

10.  Truncating mutations of hSNF5/INI1 in aggressive paediatric cancer.

Authors:  I Versteege; N Sévenet; J Lange; M F Rousseau-Merck; P Ambros; R Handgretinger; A Aurias; O Delattre
Journal:  Nature       Date:  1998-07-09       Impact factor: 49.962

View more
  10 in total

1.  Partitioning of MLX-Family Transcription Factors to Lipid Droplets Regulates Metabolic Gene Expression.

Authors:  Niklas Mejhert; Leena Kuruvilla; Katlyn R Gabriel; Shane D Elliott; Marie-Aude Guie; Huajin Wang; Zon Weng Lai; Elizabeth A Lane; Romain Christiano; Nika N Danial; Robert V Farese; Tobias C Walther
Journal:  Mol Cell       Date:  2020-02-04       Impact factor: 17.970

2.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

Authors:  Sarah K Knutson; Natalie M Warholic; Tim J Wigle; Christine R Klaus; Christina J Allain; Alejandra Raimondi; Margaret Porter Scott; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock; Kevin W Kuntz; Heike Keilhack
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

Review 3.  Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer.

Authors:  George C Prendergast; Courtney Smith; Sunil Thomas; Laura Mandik-Nayak; Lisa Laury-Kleintop; Richard Metz; Alexander J Muller
Journal:  Cancer Immunol Immunother       Date:  2014-04-08       Impact factor: 6.968

4.  SNF5 reexpression in malignant rhabdoid tumors regulates transcription of target genes by recruitment of SWI/SNF complexes and RNAPII to the transcription start site of their promoters.

Authors:  Yasumichi Kuwahara; Darmood Wei; Joel Durand; Bernard E Weissman
Journal:  Mol Cancer Res       Date:  2013-01-30       Impact factor: 5.852

Review 5.  Discovery of IDO1 Inhibitors: From Bench to Bedside.

Authors:  George C Prendergast; William P Malachowski; James B DuHadaway; Alexander J Muller
Journal:  Cancer Res       Date:  2017-12-15       Impact factor: 12.701

Review 6.  Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in Cancer.

Authors:  George C Prendergast; William J Malachowski; Arpita Mondal; Peggy Scherle; Alexander J Muller
Journal:  Int Rev Cell Mol Biol       Date:  2017-09-21       Impact factor: 6.813

Review 7.  Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

Authors:  George C Prendergast; Arpita Mondal; Souvik Dey; Lisa D Laury-Kleintop; Alexander J Muller
Journal:  Trends Cancer       Date:  2017-12-21

Review 8.  Advances in Therapeutic Targeting of Cancer Stem Cells within the Tumor Microenvironment: An Updated Review.

Authors:  Kevin Dzobo; Dimakatso Alice Senthebane; Chelene Ganz; Nicholas Ekow Thomford; Ambroise Wonkam; Collet Dandara
Journal:  Cells       Date:  2020-08-13       Impact factor: 6.600

9.  The histone deacetylase inhibitor SAHA acts in synergism with fenretinide and doxorubicin to control growth of rhabdoid tumor cells.

Authors:  Kornelius Kerl; David Ries; Rebecca Unland; Christiane Borchert; Natalia Moreno; Martin Hasselblatt; Heribert Jürgens; Marcel Kool; Dennis Görlich; Maria Eveslage; Manfred Jung; Michael Meisterernst; Michael Frühwald
Journal:  BMC Cancer       Date:  2013-06-13       Impact factor: 4.430

Review 10.  Trial watch: IDO inhibitors in cancer therapy.

Authors:  Julie Le Naour; Lorenzo Galluzzi; Laurence Zitvogel; Guido Kroemer; Erika Vacchelli
Journal:  Oncoimmunology       Date:  2020-06-14       Impact factor: 8.110

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.